Biohaven Pharmaceutical Holding Company Ltd’s US$950 Million New Funding


Maples and Calder advised Biohaven Pharmaceutical Holding Company Ltd on the British Virgin Islands legal aspects of the deal.

The transaction involved a US$500 million non-dilutive term loan with Sixth Street and a US$450 million funding agreement with Royalty Pharma. These transactions relate to separate funding arrangements with Sixth Street and Royalty Pharma with both deals closing in August 2020. The new funding will be used, in part, for the development, promotion and commercial launch of NURTEC ODT, the company’s latest FDA-approved migraine medication.

Biohaven Pharmaceutical Holding Company Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.

Chris Newton (Picture), a Corporate Partner based in the Group’s BVI office worked alongside Associate, Amel Wehden and Chartered Legal Executive, Chloe Harris in advising Biohaven, a BVI entity that is listed on the New York Stock Exchange, and other entities within the group.

Involved fees earner: Chloe Harris – Maples and Calder LLP; Chris Newton – Maples and Calder LLP; Amel Wehden – Maples and Calder LLP;

Law Firms: Maples and Calder LLP;

Clients: Biohaven Pharmaceutical Holding Company Limited;

Author: Ambrogio Visconti.